Filing Flows › Champions Oncology (CSBR) › Q1 FY27 › vs Q4 FY26
Champions Oncology (CSBR) Q1 FY27 vs Q4 FY26 (quarter over quarter)
Champions Oncology's revenue rose $1.4M (+10%) from $13.8M in Q4 FY26 to $15.2M in Q1 FY27. The biggest changes: Pharmacology services +$952K (+7%); TOS data license revenue +$597K (+202%); Other TOS revenue −$152K (-45%).
Champions Oncology, Q1 FY27: revenue $15.2M (+9% year over year), operating margin -2.7%, net loss $426K, operating cash flow −$492K. The chart draws each line against Q4 FY26, the increases inside each band.
Every line
| Line | Q1 FY27 | Q4 FY26 | Change | % |
|---|---|---|---|---|
| Pharmacology services | $14.2M | $13.2M | $952K | +7% |
| TOS data license revenue | $893K | $296K | $597K | +202% |
| Other TOS revenue | $183K | $335K | −$152K | -45% |
| Revenue | $15.2M | $13.8M | $1.4M | +10% |
| Net loss | $426K | $667K | −$241K | -36% |
| Costs & expenses | $15.7M | $14.5M | $1.1M | +8% |
| Operating costs | $15.6M | $14.4M | $1.3M | +9% |
| Income tax | $11K | $172K | −$161K | -94% |
| Cost of revenue | $7.5M | $6.8M | $724K | +11% |
| Research & development | $2.3M | $2.1M | $229K | +11% |
| Sales & marketing | $3.1M | $2.8M | $292K | +10% |
| General & admin | $2.7M | $2.6M | $40K | +2% |
| Operating cash sources | $1.6M | $2.7M | −$1.1M | -41% |
| Depreciation & amortization | $314K | $300K | $14K | +5% |
| Share-based compensation | $766K | $357K | $409K | +115% |
| Cash used in operations | $492K | $2.0M | −$1.5M | -75% |
| Net loss absorbed | $426K | $667K | −$241K | -36% |
| Working capital & other | $1.1M | $2.0M | −$842K | -42% |
Questions
How much did Champions Oncology's revenue grow quarter over quarter in Q1 FY27?
Champions Oncology's revenue rose $1.4M (+10%) from $13.8M in Q4 FY26 to $15.2M in Q1 FY27.
What drove Champions Oncology's revenue change in Q1 FY27?
Pharmacology services +$952K (+7%); TOS data license revenue +$597K (+202%); Other TOS revenue −$152K (-45%).